New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
08:33 EDTCBMGCellular Biomedicine completes enrollment in ReJoin Phase IIb clinical trial
Cellular Biomedicine has completed the patient enrollment required for its Phase IIb trial to further evaluate the safety and efficacy of their proprietary adipose-derived mesenchymal precursor cell-based therapy ReJoin for Knee Osteoarthritis. The Phase I/IIa clinical trial for this therapy was completed in 4Q13. The primary endpoints for this trial are knee-related pain, stiffness and function.
News For CBMG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2015
09:40 EDTCBMGCellular Biomedicine announces new facility in Beijing
Cellular Biomedicine announced that the company, in anticipation of growth in the Beijing vicinity and further development of the CAR-T platform, has signed a new five-year lease for a 15,000 square feet site slated for the company's third GMP facility which will also expanded staffing in the Life Science Park, Changping District, Beijing, China. Approximately half of the site will be a GMP equipped facility to support clinical batch production and commercial scale manufacturing. We expect to complete the state-of-the-art GMP facility in Q3 this year.
April 20, 2015
09:22 EDTCBMGCellular Biomedicine engages Huntsworth Health to build KOL advocacy for trials
Cellular Biomedicine announced that the company has engaged Huntsworth Health, a global healthcare marketing and communications agency to build a global KOL advocacy campaign for CBMG's ReJoin human adipose-derived mesenchymal progenitor cell, or haMPC, clinical trials for the treatment of Knee Osteoarthritis.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use